(Q34666866)

English

Phase I trial of lenalidomide in pediatric patients with recurrent, refractory, or progressive primary CNS tumors: Pediatric Brain Tumor Consortium study PBTC-018.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Phase I trial of lenalidomide in pediatric patients with recurrent, refractory, or progressive primary CNS tumors: Pediatric Brain Tumor Consortium study PBTC-018. (English)

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

phase I clinical trial

0 references

1 reference

based on heuristic

inferred from title

8

object named as

Susan M Blaney

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

author name string

Katherine E Warren

1

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Stewart Goldman

2

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Ian F Pollack

3

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Jason Fangusaro

4

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Paula Schaiquevich

5

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Clinton F Stewart

6

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Dana Wallace

7

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Roger Packer

9

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Tobey Macdonald

10

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Regina Jakacki

11

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

James M Boyett

12

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Larry E Kun

13

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

language of work or name

0 references

publication date

13 December 2010

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Journal of Clinical Oncology

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

29

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

324-329

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

The anti-cancer drug lenalidomide inhibits angiogenesis and metastasis via multiple inhibitory effects on endothelial cell function in normoxic and hypoxic conditions

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3056466

7 July 2018

Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3056466

7 July 2018

Lenalidomide therapy for metastatic renal cell carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3056466

7 July 2018

Thalidomide and lenalidomide: Mechanism-based potential drug combinations

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3056466

7 July 2018

Immunomodulatory drugs Revlimid (lenalidomide) and CC-4047 induce apoptosis of both hematological and solid tumor cells through NK cell activation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3056466

7 July 2018

Preclinical studies of novel targeted therapies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3056466

7 July 2018

Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children's Oncology Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3056466

7 July 2018

Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3056466

7 July 2018

Lenalidomide: an immunomodulatory drug

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3056466

7 July 2018

Lenalidomide and thalidomide: mechanisms of action--similarities and differences

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3056466

7 July 2018

Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3056466

7 July 2018

Phase I study to determine the safety, tolerability and immunostimulatory activity of thalidomide analogue CC-5013 in patients with metastatic malignant melanoma and other advanced cancers

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3056466

7 July 2018

Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3056466

7 July 2018

Phase II trial of lenalidomide in patients with metastatic renal cell carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3056466

26 October 2018

A phase I trial of lenalidomide in patients with recurrent primary central nervous system tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3056466

26 October 2018

Determination of CC-5013, an analogue of thalidomide, in human plasma by liquid chromatography-mass spectrometry

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3056466

26 October 2018

Immunomodulatory drug costimulates T cells via the B7-CD28 pathway

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3056466

26 October 2018

Practical implementation of a modified continual reassessment method for dose-finding trials.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3056466

26 October 2018

Lenalidomide and venous thrombosis in multiple myeloma

1 reference

https://pubmed.ncbi.nlm.nih.gov/21149652

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Toxicity profile of the immunomodulatory thalidomide analogue, lenalidomide: phase I clinical trial of three dosing schedules in patients with solid malignancies

1 reference

https://pubmed.ncbi.nlm.nih.gov/21149652

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II study of lenalidomide in patients with metastatic renal cell carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/21149652

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Safety and efficacy of lenalidomide (Revlimid) in recurrent ovarian and primary peritoneal carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/21149652

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I study of lenalidomide in solid tumors

1 reference

https://pubmed.ncbi.nlm.nih.gov/21149652

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1200/JCO.2010.31.3601

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34666866&oldid=1961588842"